Skip to content

BridgeBio Pharma BBIO Contract Liabilities

Contract Liabilities at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
$75.75M-46.2%
Arrowhead Research logo
Arrowhead ResearchARWR

Segments

By product

See full
Research and Development Services$2.7M

Other financials

Income statement

See full
Revenue$194.5M+66.8%
Gross profit$184.6M+61.9%
Operating income-$106.0M-1.5%
Net income-$166.6M+1.8%
EPS (diluted)-$0.84+4.5%

Balance sheet

See full
Cash & equivalents$882.0M+62.5%
Total debt$3.3B+32,101%
Total equity-$2.3B-38.2%
Total assets$1.4B+55.5%

Cash flow

See full
Operating cash flow-$197.3M+1.0%
CapEx$69.0K
Free cash flow-$197.3M+0.9%

Valuation

See full
Market cap$12.98B+119%
Enterprise value$15.36B+178%
P/S22.4×-24.1×

Profitability

See full
Gross margin95.1%-0.2pp
Operating margin-90.5%-41.2pp
Net margin-125.9%-54.5pp
FCF margin-76.8%

Returns & leverage

See full
Return on equity-216.8%
Debt / equity
Current ratio1.5×-3.0×

Where this comes from

Reported directly by BridgeBio Pharma in its filing.

Tagged under the XBRL concept us-gaap:ContractWithCustomerLiabilityNoncurrent.

The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about BridgeBio Pharma's contract liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BridgeBio Pharma's contract liabilities?
BridgeBio Pharma (BBIO) reported contract liabilities of $11.78M in Q1 2026.
What does contract liabilities mean?
Money received from customers for goods or services that have not yet been delivered.
How do you interpret contract liabilities?
An increase suggests strong future revenue visibility, while a decrease may indicate faster fulfillment or slowing sales bookings.
How does contract liabilities compare across companies?
Common in biotech companies with collaboration or licensing agreements involving upfront payments.